口服有活性的血管紧张素转化酶(ACE)抑制剂,如甲巯丙脯酸和 enalapril 代表了高血压和充血性心衰治疗的显著进展。enalapril 和甲巯丙脯酸不同,它是前药,通过肝脏酯解转化成有活性、吸收较差的双酸enalaprilat。enalaprilat 作用比甲巯丙脯酸强,消除较慢,不含巯基。在 enalapril 后又有许多新 ACE 抑制剂,其中大多与 enalapril 相似,也是前药,通过肝脏酯解转化为有活性、更难吸收的双酸代谢物。delapril 有两个活性代谢物,alacepril 在 Orally active inhibitors of angiotensin-converting enzyme (ACE), such as captopril and enalapril, represent a significant advance in the treatment of hypertension and congestive heart failure. In contrast to captopril, enalapril is a prodrug that is converted into an active, poorly absorbed, double-acid enalaprilat via the liver. Enalaprilat is more potent than captopril, slower to eliminate and does not contain a thiol group. After enalapril there are many new ACE inhibitors, most of which are similar to enalapril and are prodrugs, converted by the liver to active, less digestible diacid metabolites. delapril has two active metabolites, alacepril at